Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
US Department of Justice
Deloitte
Citi
McKesson
Teva
Dow
Colorcon

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202033

« Back to Dashboard

NDA 202033 describes METOPROLOL SUCCINATE, which is a drug marketed by Spil, Actavis Elizabeth, Actavis Labs Fl Inc, Dr Reddys Labs Ltd, Mylan Pharms Inc, Nesher Pharms, Novast Labs Ltd, Reddys, Sandoz, Wockhardt, and Zydus Pharms Usa Inc, and is included in fourteen NDAs. It is available from thirty-seven suppliers. There are two patents protecting this drug. Additional details are available on the METOPROLOL SUCCINATE profile page.

The generic ingredient in METOPROLOL SUCCINATE is metoprolol succinate. There are fifty-nine drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.
Summary for 202033
Tradename:METOPROLOL SUCCINATE
Applicant:Mylan Pharms Inc
Ingredient:metoprolol succinate
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 202033
Mechanism of ActionAdrenergic beta-Antagonists
Suppliers and Packaging for NDA: 202033
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 202033 ANDA Mylan Institutional Inc. 51079-169 N 51079-169-20
METOPROLOL SUCCINATE metoprolol succinate TABLET, EXTENDED RELEASE;ORAL 202033 ANDA Mylan Institutional Inc. 51079-170 N 51079-170-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 25MG TARTRATE
Approval Date:Dec 15, 2011TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG TARTRATE
Approval Date:Dec 15, 2011TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 100MG TARTRATE
Approval Date:Dec 15, 2011TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Merck
Covington
Federal Trade Commission
Moodys
Boehringer Ingelheim
Citi
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.